EntreMed Presents Interim Results for Phase 2 Carcinoid T... ( Combination of Panzem(R) NCD and...)

EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study

Date:1/28/2008

Combination of Panzem(R) NCD and Avastin(R) May Slow Tumor Growth

ROCKVILLE, Md., Jan. 28 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of interim results for its Phase 2 multi-center study combining Panzem(R) NCD with Avastin(R) (bevacizumab) in patients with advanced or metastatic carcinoid tumors. The data were presented by principal investigator, Matthew Kulke, M.D., from the Dana-Farber Cancer Institute, during the 2008 Gastrointestinal Cancers Symposium being held in Orlando, Florida.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Thirty-one patients received oral Panzem(R) NCD daily in combination with Avastin(R) administered intravenously every other week. Of the 29 evaluable patients, 27 patients (87%) had stable disease and 2 patients (7%) had progressive disease as their best response. Fourteen of the 31 patients have been treated for at least six months, and 9 of the 14 have been treated for over one year. Results demonstrate that the combination of Panzem(R) NCD and Avastin(R) is well tolerated in advanced carcinoid tumor patients. The current analysis includes median follow up time over 8 months. Median progression-free survival and overall survival have not yet been reached. Enrollment in the trial is closed and 9 patients remain on study.

Carolyn F. Sidor, M.D., M.B.A., EntreMed's Vice President and Chief Medical Officer, commented on the results, "This study was designed to evaluate the combination of two antiangiogenic agents, Panzem(R)
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
2. EntreMed Appoints Senior Vice President of Research and Development
3. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
4. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. BAI Retail Delivery Conference Softpro Presents Next Generation Signature Tablet
7. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
8. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
9. Arpida Presents Preclinical Data on AR-2474 at ICAAC
10. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
11. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic

Post Your Comments:

(Date:6/18/2013)... June 18, 2013 Tabletop SEMs are ... SEMs but have limited performance and capability such as ... size SEMs would normally provide better imaging performance and ... operate and have a higher cost of maintenance. ... gap between these two types of SEM product, offering ...

(Date:6/18/2013)... HONG KONG, June 18, 2013 China Cord ... the "Company"), China,s leading provider of cord blood collection, ... storage services, today announced its preliminary unaudited financial results ... year 2013 ended March 31, 2013. ... for the fourth quarter of fiscal 2013 increased by ...

(Date:6/18/2013)... Angeles, CA (PRWEB) June 18, 2013 (PRWEB) June ... construction’s #1 time and attendance system in North ... software that shares employee data and payroll records ... AccountLinx Plus automates ExakTime software setup ... The software imports employee data from a business’ ...

(Date:6/18/2013)... Demanding industrial and environmental conditions are ... Sapphire and Glass Ball Lenses, now available in an ... Company , of Philadelphia , PA. , Optical Ball ... light beams without the need for direct physical contact. ... (9 mohs) make it the ideal choice for fiber-optic ...

[0] Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes [0] China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 [0] ExakTime Introduces AccountLinx Plus [0] Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors

... BAX ) announced today that its Board of ... of the company,s,common stock to be executed upon completion ... less than $700 million of remaining authorization under its,previous ... March,2007. Shares will be repurchased in the open market ...

... 18 /PRNewswire/ - Aegera Therapeutics announced today,the ... trial for AEG33773, a,novel, orally bioavailable small ... diabetic neuropathy. The Phase I study will ... AEG33773 using a randomized,double blind, placebo controlled, ...

... siRNA Targeting of, VEGF Expression, Further Strengthening OPKO,s RNAi Intellectual Property ... ... OPKO Health, Inc. (Amex: OPK ),today announced that it has been ... for methods related to the use and,administration of small interfering RNAs (siRNAs) ...

Cached Biology Technology:Baxter's Board of Directors Approves New Share Repurchase Authorization of $2 Billion 2 Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain 2 OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib 2 OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib 3 OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib 4

Baxter's Board of Directors Approves New Share Repurchase Authorization of $2 Billion Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib

(Date:6/19/2013)... new variety of canary seeds bred specifically for human ... ideal for people with celiac disease (CD), scientists have ... of Agricultural and Food Chemistry . , Joyce ... 3 million people in the United States alone have ... wheat, barley, rye and other grains that contain gluten-related ...

(Date:6/19/2013)... A Cornell University study offers further proof that the ... 6 million years ago was profoundly influenced by mutations ... on and off. , The study, published June 9 ... 40-year-old hypothesis that regulation of genes must play an ... between humans and chimps in the proteins produced by ...

(Date:6/19/2013)... 2013 Elsevier, a world-leading provider of scientific, technical ... announce the launch of a new open access journal, ... GeoResJ , Elsevier,s earth and planetary science journals ... journal aims to provide a forum for rapid publication ... The journal will be co-edited by six Executive Editors, ...

Breaking Biology News(10 mins):New research backs theory that genetic 'switches' play big role in human evolution 2 New research backs theory that genetic 'switches' play big role in human evolution 3

[0] New canary seed is ideal for gluten-free diets in celiac disease [0] New research backs theory that genetic 'switches' play big role in human evolution [0] Elsevier launches open access journal: GeoResJ

... genetic diversity in crops is traditional practice for agriculture ... develop breeding programs with great care for the security ... numerous risks the world,s food supplies face with the ... essential as an insurance against unforeseeable changes in the ...

... -- A Duke University-led team has brought powerful software ... Working together, computer scientists and biochemists have developed and ... to change the machinery that bacteria use to make ... set of computer rules known as the algorithm "K*" ...

... distinguishes itself as the fastest growing greenhouse gas in ... emissions depends on our ability to measure the increase ... increase. Until the late 1950s when high ... whether the industrial revolution and the associated increase in ...

Cached Biology News:Identifying mega-targets for high-yield plant breeding 2 Duke software dramatically speeds enzyme design 2 Duke software dramatically speeds enzyme design 3 Carbon accounting from atmospheric measurements -- the aircraft perspective 2

Identifying mega-targets for high-yield plant breeding Duke software dramatically speeds enzyme design Carbon accounting from atmospheric measurements -- the aircraft perspective

Includes a choice of any 3 EasySep mouse selection kits and EasySep magnet...

... PYREX trypsinizing flasks are used ... into cell suspensions by digestion ... neck accepts cotton plugs. Four ... • Height of Baffles mm ...

... the efficient enrichment of functional endoplasmic ... cell culture. The isolated ER are ... metabolic pathway analysis. Metabolic abnornalities of ... children, cystic fibrosis and many more ...

Plasmid expressing PLAP reporter gene....

Biology Products:

EasySep Mouse Combo Starter, Kit from StemCell Technologies, Inc.Pyrex brand baffled trypsinizing flask, with beaded neck from Sigma-Aldrich Endoplasmic Reticulum Isolation Kit from Sigma-Aldrich pORF-PLAP from InvivoGen